Chandler D. Robinson, MD MBA MSc Co-Founder and Chief Executive Officer Dr. Robinson, in 2010, co-founded and was CEO of Tactic Pharma. He helped lead Tactic through a successful sale of its lead compound. His passion is leveraging his interests in medicine, science, and finance to help bring new therapeutics to patients. The compound Dr. Robinson researched at Northwestern University as an undergraduate, and published on in Science, is currently entering a Phase III clinical trial for Wilson Disease. Among his previous experiences, Dr. Robinson in 2008 worked at Onyx Pharmaceuticals in their Nexavar marketing division, from 2008-2009 as a co-manager of a healthcare clinic in San Jose CA, from 2004 to present as Founder and President of an undergraduate research focused non-profit, and from 2006 to 2007 at Bear Stearns investment bank. He was previously on the board of Wilson Therapeutics, and is currently on the board of Northwestern University's Chemistry of Life Processes Institute. Dr. Robinson graduated summa cum laude from Northwestern University, earned a master's degree in International Health Policy and Health Economics from the London School of Economics on a Fulbright Scholarship, an MBA from Cambridge University on a Gates Scholarship, and an MD from Stanford University.
Dr. Starr has helped bring 6 orphan product drugs to market, and as co-founder and CEO of Raptor Pharmaceuticals (recently purchased by Horizon Pharma), oversaw the approval, launch, and successful commercialization of Procysbi®. He served as Raptor’s initial CEO since its inception in 2006 through 2014 and continued to serve on Raptor’s board of directors until Raptor was sold to Horizon Pharma in October 2016. Dr. Starr co-founded BioMarin Pharmaceutical Inc. in 1997 where he last served as Senior Vice President and Chief Scientific Officer until starting Raptor in 2006. As Senior Vice President at BioMarin, Dr. Starr was responsible for managing a Scientific Operations team of 181 research, process development, manufacturing and quality personnel through the successful development of commercial manufacturing processes for its enzyme replacement and small molecule products, and supervised the cGMP design, construction and licensing of BioMarin's proprietary biological manufacturing facility. From 1991 to 1998, Dr. Starr supervised research and commercial programs at BioMarin's predecessor company, Glyko, Inc., where he served as Vice President of Research and Development. Prior to his tenure at Glyko, Inc., Dr. Starr was a National Research Council Associate at the National Institutes of Health. Dr. Starr earned a B.S. from Syracuse University and a Ph.D. in Biochemistry and Molecular Biology from the State University of New York Health Science Center, in Syracuse, New York.
Chief Scientific Officer
Dr. Mazar has spent twenty-eight years working on drug discovery and development at the interface of academia and industry and has founded or co-founded eight start-up companies including Tactic Pharma to commercialize new drug discoveries. He is internationally recognized for his translational research on the role of the urokinase plasminogen activator (uPA) system in tumor progression as well as mechanisms of cancer invasion and metastasis. Prior to his roles as a faculty member in the Chemistry of Life Processes Institute and the Department of Pharmacology, Feinberg School of Medicine at Northwestern University and co-founding Tactic Pharma in 2010, Dr. Mazar was the Chief Scientific Officer at Attenuon, LLC in San Diego from 2000 to 2009 and led discovery and development efforts resulting in three drugs entering oncology clinical trials. Dr. Mazar has now overseen 18 IND enabling efforts, many of these focused on drugs discovered in academia.
Kim R. Tsuchimoto Chief Financial Officer Ms. Tsuchimoto has spent over nine years at Raptor Pharmaceuticals, as its Chief Financial Officer from Raptor’s inception in May 2006 until August 2012, as Raptor’s Vice President of International Finance, Tax & Treasury from September 2012 to February 2015, and lastly served as Raptor’s Vice President, Financial Planning & Analysis and Internal Controls from February to May 2015. At Raptor, Ms. Tsuchimoto completed: two reverse mergers, one to initially trade on the OTCBB, the second to gain Raptor’s Nasdaq listing; over $100 million of financings (primarily equity); one clinical asset purchase; and one clinical platform asset license, which later became Raptor’s first commercial product and lead program. Ms. Tsuchimoto has drafted numerous SEC mandated reports such as 10-Ks, 10-Qs, Form 4s, S-1s, S-3s and prospectus supplements. Prior to Raptor, Ms. Tsuchimoto spent eight years at BioMarin Pharmaceutical Inc. and its predecessor, Glyko, Inc., where she held the positions of Vice President-Treasurer, Vice President-Controller and Controller. At BioMarin, Ms. Tsuchimoto provided due diligence for the company’s IPO in 1999 and helped close BioMarin’s first $500 million of financing between 1997 and 2005. Ms. Tsuchimoto was responsible for BioMarin’s SEC reporting, corporate compliance, 10(b)5-1 trading plans and was BioMarin’s primary liaison with external legal counsel and auditors in the company’s early years. Prior to Glyko, she served as Controller at a few companies outside the biotech industry. She began her career as a staff accountant in a local certified public accounting firm. Ms. Tsuchimoto received a B.S. in Business Administration from San Francisco State University. She holds an inactive California Certified Public Accountant license.
Dr. Rioux has been deeply involved in the development of drugs for rare diseases over the last 20 years. His background includes development of drugs and biologic products for various indications across neurodegenerative diseases, immunology, pain management, oncology and metabolic diseases. He was most recently Senior Vice President, Global Clinical Development at ArmaGen, Inc., a company focused on the development of fusion proteins for the treatment of lysosomal storage diseases, and before that, Chief Medical Officer at Raptor Pharmaceuticals where he was responsible for securing regulatory approval of PROCYSBI, a delayed-release cysteamine for the treatment of a lysosomal storage disease, nephropathic cystinosis, in both the U.S. and Europe. He previously served as Chief Medical Officer at Edison Pharmaceuticals, and as Vice President, Clinical at Repligen, where he gained significant orphan disease experience in mitochondrial diseases as well as in autism, and auto-immune diseases. After several years as a clinical researcher at INSERM (France), he started his career in the pharmaceutical industry at Biogen, working on multiple sclerosis, before joining Variagenics, Inc., one of the first pharmacogenomic companies. Dr. Rioux received his Medical Education at Faculte de Medecine Pitie-Salpetriere, his Ph.D. in Mathematical Statistics at Faculte des Sciences, and his Degree of Pharmacology (pharmacokinetics and clinical pharmacology) at Faculte de Medecine Pitie-Salpetriere.
Ms. Anderson has more than 25 years of experience in the biotech and pharmaceutical industry, with expertise in oncology drug development. From 2008 to 2017, she was with OncoGenex Pharmaceuticals, where she most recently served as Vice President, Clinical Operations. Prior to joining OncoGenex, Ms. Anderson held clinical trial management positions at Sonus Pharmaceuticals, Xcyte Therapies and Immunex, including the oversight of global clinical operations, drug safety and data management. She has a laboratory research background and began her career at the University of Pennsylvania. Ms. Anderson earned a B.S. in Biology from the University of Vermont and is completing her Masters in Biotech Enterprise (expected 2018) from Johns Hopkins University.
Mr. Brown is the Co-Founder, and since 1994 served as Chairman, and CEO of Euronet Worldwide, a multi-billion dollar NASDAQ listed company. He is an accomplished serial entrepreneur who has a Master of Science in molecular and cellular biology. He had, before the age of 40, successfully founded, and led as CEO two companies through their initial public offering.
Mr. Anderson has more than 30 years of biopharmaceutical sector experience, primarily focused in financial management. He was CFO at such notable companies as BioMarin and Dow Pharmaceutical Sciences, Inc. (now a wholly owned subsidiary of Valeant Pharmaceuticals International), and was a board member and chair of the audit committee for Raptor Pharmaceutical Corp. (now a wholly owned subsidiary of Horizon Pharma plc).
Mr. Klausner served as Chief Executive Officer of Gem Pharmaceuticals, LLC (“Gem”) from 2012 until Gem’s drug development assets were acquired by Monopar in 2017. In addition to his role at Gem, he was CEO of Jade Therapeutics Inc. (“Jade”) from 2012-2015. Previously, Mr. Klausner spent a total of 18 years at the life science venture capital firms Domain Associates and Pappas Ventures, where he was involved in the investment in and subsequent nurturing of a variety of biotechnology, specialty pharmaceutical, and medical device companies.